These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24828935)

  • 1. Hypercalcemia in an immobilized elderly woman with renal dysfunction receiving vitamin D3 analogue and bisphosphonate: a diagnostic challenge.
    Okubo Y; Kakizawa M; Saito Y; Yamamoto M; Nakasone Y; Sato Y; Yamauchi K; Aizawa T
    J Am Geriatr Soc; 2014 May; 62(5):989-91. PubMed ID: 24828935
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypercalcaemia-induced acute kidney injury in an older patient with osteoporosis treated with alfacalcidol for denosumab-induced hypocalcaemia.
    Yamada S; Matsuo M; Tokumoto M; Ooboshi H
    Nephrology (Carlton); 2017 Jul; 22(7):572-573. PubMed ID: 28621008
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypocalcaemic tetany occurring post a single denosumab dose in a patient with stage 4 chronic kidney disease, followed by calcium- and calcitriol-induced hypercalcaemia.
    Lambe G; Malvathu R; Thomas HM; Graves A
    Nephrology (Carlton); 2015 Aug; 20(8):583-4. PubMed ID: 26194986
    [No Abstract]   [Full Text] [Related]  

  • 4. [Adverse events of drugs for the treatment of osteoporosis].
    Nakamura T
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():304-10. PubMed ID: 18074553
    [No Abstract]   [Full Text] [Related]  

  • 5. [Bisphosphonates. Drugs for the treatment of disorders of calcium and bone metabolism].
    Warneke G; Henning HV
    Internist (Berl); 1992 Jun; 33(6):441-5. PubMed ID: 1385800
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment and prevention of osteoporosis in patients with decreased renal function].
    Vestergaard P; Eiken PA
    Ugeskr Laeger; 2008 Jan; 170(4):227-30. PubMed ID: 18282452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged vitamin D intoxication: presentation, pathogenesis and progress.
    Bell DA; Crooke MJ; Hay N; Glendenning P
    Intern Med J; 2013 Oct; 43(10):1148-50. PubMed ID: 24134173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Activate vitamin D3 or bisphosphonate in glucocorticoid-induced osteoporosis].
    Imanishi Y; Nishizawa Y
    Clin Calcium; 2006 Nov; 16(11):1844-50. PubMed ID: 17079851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Active vitamin D3 therapy for gulucocorticoid-induced osteoporosis].
    Nakayama H
    Clin Calcium; 2006 Jul; 16(7):1201-7. PubMed ID: 16816482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hypercalciuria--nephrocalcinosis-- and calcium calculi of the kidney. Differential diagnosis and clinical aspects of pathological renal calcium transport].
    Heidbreder E; Hennemann H; Heidland A
    Dtsch Med Wochenschr; 1974 Mar; 99(12):586-590. PubMed ID: 4365704
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of pamidronate in a rat hypercalcemia model induced by cholecalciferol.
    Okada M; Noguchi S; Hasegawa Y; Inukai T
    Arzneimittelforschung; 1992 Apr; 42(4):543-6. PubMed ID: 1322674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of postmenopausal osteoporosis with vitamin D and severe hypercalcemia.
    Buysschaert M; Lejeune D; Esselinckx W; Lebacq EG
    Acta Clin Belg; 1984; 39(3):171-3. PubMed ID: 6091383
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hypercalcemia due to chronic vitamin A use by an elderly patient with renal insufficiency].
    Beijer C; Planken EV
    Ned Tijdschr Geneeskd; 2001 Jan; 145(2):90-3. PubMed ID: 11225264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of pamidronate in patients with renal failure and hypercalcemia.
    Machado CE; Flombaum CD
    Clin Nephrol; 1996 Mar; 45(3):175-9. PubMed ID: 8706358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Absolute risk for fracture and WHO guideline. Pharmacological intervention to prevent osteoporotic fractures in the elderly].
    Hosoi T;
    Clin Calcium; 2007 Jul; 17(7):1098-104. PubMed ID: 17607078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Side-effects of therapeutic agents for osteoporosis].
    Yano S; Sugimoto T
    Nihon Rinsho; 2012 Aug; 70 Suppl 6():224-9. PubMed ID: 23156513
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of osteoporosis with active vitamin D3].
    Katagiri H
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():392-6. PubMed ID: 15035158
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute hypercalcemia simulating basilar-artery insufficiency.
    Streeto JM
    N Engl J Med; 1969 Feb; 280(8):427-9. PubMed ID: 5304106
    [No Abstract]   [Full Text] [Related]  

  • 19. Hypercalcemia and acute kidney injury induced by eldecalcitol in patients with osteoporosis: a case series of 32 patients at a single facility.
    Aihara S; Yamada S; Oka H; Kamimura T; Nakano T; Tsuruya K; Harada A
    Ren Fail; 2019 Nov; 41(1):88-97. PubMed ID: 30909788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency.
    Ralston SH; Binkley N; Boonen S; Kiel DP; Reginster JY; Roux C; Chen L; Rosenberg E; Santora A;
    Calcif Tissue Int; 2011 Jun; 88(6):485-94. PubMed ID: 21479913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.